Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STACY L MOULDER

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1184725111
CMS profile
8729
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$9.76

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Education $9.76 1

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
PFIZER INC. $9.76 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STACY L MOULDER

NPI 1184725111 · CMS profile ID 8729

Allopathic & Osteopathic Physicians / Internal Medicine

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1184725111?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STACY L MOULDER, NPI 1184725111, CMS profile ID 8729. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1184725111?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). STACY L MOULDER, NPI 1184725111, CMS profile ID 8729. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1184725111?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
STACY L MOULDER, NPI 1184725111, CMS profile ID 8729, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1184725111?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $9.76 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $9.7603/11/2020 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743457439 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $423.69 13
PY2020 $9.76 1
PY2021 $11.92 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021
Generated from
OP_DTL_GNRL_PGYR2021_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $17,570.20 1
PY2023 Principal investigator $21,186.93 3
PY2022 Principal investigator $26,763.95 2
PY2021 Principal investigator $176,461.79 3
PY2020 Recipient $1,500.00 1
PY2020 Principal investigator $247,942.50 43
PY2019 Recipient $631.79 2
PY2019 Principal investigator $717,818.64 63

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

65 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $11.00 12/27/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671692811
Principal investigator 1 PFIZER INC. $11.00 12/26/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671692957
Principal investigator 1 Merck Sharp & Dohme Corporation $500.00 12/16/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with 1 cm Residual Invasive Cancer or Positive Lymph Nodes pN1mic After Neoadjuvant Chemotherapy No dispute reported 06/30/2026 714553083
Principal investigator 1 PFIZER INC. $11.00 12/04/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671692769
Principal investigator 1 PFIZER INC. $1,400.00 11/28/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671692875
Principal investigator 1 PFIZER INC. $11.00 11/25/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671693285
Principal investigator 1 PFIZER INC. $11.00 11/19/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671692703
Principal investigator 1 Merck Sharp & Dohme Corporation $30.00 11/12/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with 1 cm Residual Invasive Cancer or Positive Lymph Nodes pN1mic After Neoadjuvant Chemotherapy No dispute reported 06/30/2026 714553079
Principal investigator 1 Merck Sharp & Dohme Corporation $60.00 11/12/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with 1 cm Residual Invasive Cancer or Positive Lymph Nodes pN1mic After Neoadjuvant Chemotherapy No dispute reported 06/30/2026 714553081
Principal investigator 1 PFIZER INC. $11.00 11/12/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671692741
Principal investigator 1 PFIZER INC. $11.00 11/06/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671692805
Principal investigator 1 PFIZER INC. $4,731.25 11/05/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671692877
Principal investigator 1 PFIZER INC. $11.00 10/30/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671693029
Principal investigator 1 Merck Sharp & Dohme Corporation $30.00 10/21/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with 1 cm Residual Invasive Cancer or Positive Lymph Nodes pN1mic After Neoadjuvant Chemotherapy No dispute reported 06/30/2026 714553075
Principal investigator 1 Merck Sharp & Dohme Corporation $60.00 10/21/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with 1 cm Residual Invasive Cancer or Positive Lymph Nodes pN1mic After Neoadjuvant Chemotherapy No dispute reported 06/30/2026 714553077
Principal investigator 1 PFIZER INC. $11.00 10/16/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671693199
Principal investigator 1 PFIZER INC. $11.00 10/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671692803
Principal investigator 1 PFIZER INC. $11.00 10/02/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671692767
Principal investigator 1 PFIZER INC. $11.00 09/18/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671692735
Principal investigator 1 Seattle Genetics, Inc. $683.79 09/18/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 1b, open-label study to assess the safety and tolerability of ONT-380 combined with capecitabine and trastuzumab, alone and in combination in HER2 metastatic breast cancer No dispute reported 06/30/2026 678823691
Principal investigator 1 Seattle Genetics, Inc. $16,041.17 09/18/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 1b, open-label study to assess the safety and tolerability of ONT-380 combined with capecitabine and trastuzumab, alone and in combination in HER2 metastatic breast cancer No dispute reported 06/30/2026 678823693
Principal investigator 1 PFIZER INC. $11.00 09/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671692955
Principal investigator 1 Merck Sharp & Dohme Corporation $41.50 08/29/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with 1 cm Residual Invasive Cancer or Positive Lymph Nodes pN1mic After Neoadjuvant Chemotherapy No dispute reported 06/30/2026 714553071
Principal investigator 1 Merck Sharp & Dohme Corporation $50.00 08/29/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with 1 cm Residual Invasive Cancer or Positive Lymph Nodes pN1mic After Neoadjuvant Chemotherapy No dispute reported 06/30/2026 714553073
Principal investigator 1 PFIZER INC. $11.00 08/28/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671692739
Principal investigator 1 PFIZER INC. $2,800.00 08/26/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671692841
Principal investigator 1 PFIZER INC. $11.00 08/21/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671692737
Principal investigator 1 PFIZER INC. $11.00 08/07/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671692839
Principal investigator 1 PFIZER INC. $22.00 07/31/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671692705
Principal investigator 1 PFIZER INC. $11.00 07/23/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671693283
Principal investigator 1 Merck Sharp & Dohme Corporation $50.00 07/16/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with 1 cm Residual Invasive Cancer or Positive Lymph Nodes pN1mic After Neoadjuvant Chemotherapy No dispute reported 06/30/2026 714553069
Principal investigator 1 PFIZER INC. $2,100.00 07/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671653775
Principal investigator 1 PFIZER INC. $11.00 07/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671692991
Principal investigator 1 PFIZER INC. $11.00 07/02/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671693281
Principal investigator 1 PFIZER INC. $11.00 06/26/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671692709
Principal investigator 1 PFIZER INC. $2,800.00 06/12/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671657671
Principal investigator 1 PFIZER INC. $11.00 06/11/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671692809
Principal investigator 1 PFIZER INC. $11.00 06/06/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671692707
Recipient NOVARTIS PHARMACEUTICALS CORPORATION $478.79 06/02/2019 Covered Recipient Physician RESEARCH RELATED PUBLICATIONS SUPPORT No dispute reported 06/30/2026 717204241
Principal investigator 1 Merck Sharp & Dohme Corporation $500.00 05/30/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with 1 cm Residual Invasive Cancer or Positive Lymph Nodes pN1mic After Neoadjuvant Chemotherapy No dispute reported 06/30/2026 714553067
Principal investigator 1 PFIZER INC. $11.00 05/21/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671693197
Principal investigator 1 PFIZER INC. $11.00 05/16/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671693241
Principal investigator 1 PFIZER INC. $2,100.00 05/07/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671653773
Principal investigator 1 PFIZER INC. $11.00 05/07/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671693243
Principal investigator 1 PFIZER INC. $11.00 05/01/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671692771
Principal investigator 1 Merck Sharp & Dohme Corporation $100.00 04/25/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with 1 cm Residual Invasive Cancer or Positive Lymph Nodes pN1mic After Neoadjuvant Chemotherapy No dispute reported 06/30/2026 714553065
Principal investigator 1 Merck Sharp & Dohme Corporation $50.00 04/18/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with 1 cm Residual Invasive Cancer or Positive Lymph Nodes pN1mic After Neoadjuvant Chemotherapy No dispute reported 06/30/2026 714553063
Principal investigator 1 PFIZER INC. $11.00 04/16/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671692989
Principal investigator 1 PFIZER INC. $22.00 04/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671692921
Principal investigator 1 PFIZER INC. $2,800.00 04/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671655367
Principal investigator 1 Merck Sharp & Dohme Corporation $41.50 04/05/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with 1 cm Residual Invasive Cancer or Positive Lymph Nodes pN1mic After Neoadjuvant Chemotherapy No dispute reported 06/30/2026 714553061
Principal investigator 1 PFIZER INC. $11.00 04/02/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671692773
Principal investigator 1 PFIZER INC. $11.00 03/19/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671655073
Principal investigator 1 PFIZER INC. $7,531.25 03/12/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671655229
Principal investigator 1 PFIZER INC. $11.00 03/12/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671655251
Principal investigator 1 PFIZER INC. $11.00 03/05/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671654793
Principal investigator 1 PFIZER INC. $1,400.00 02/14/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671655227
Recipient NOVARTIS PHARMACEUTICALS CORPORATION $153.00 02/12/2019 Covered Recipient Physician RESEARCH RELATED PUBLICATIONS SUPPORT No dispute reported 06/30/2026 717204239
Principal investigator 1 PFIZER INC. $44.00 02/06/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671654933
Principal investigator 1 PFIZER INC. $7.50 02/05/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671655259
Principal investigator 1 Novartis Pharmaceuticals Corporation $668,827.93 01/22/2019 Non-covered Recipient Entity
UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
WOMENS TRIPLE NEGATIVE FIRST LINE STUDY A PHASE II TRIAL OF LIPOSOMAL DOXORUBICIN BEVACIZUMAB AND EVEROLIMUS DAE IN PATIENTS WITH LOCALIZED TRIPLE NEGATIVE BREAST CANCER TNBC WITH TUMORS PREDICTED INSENSITIVE TO STANDARD NEOADJUVANT CHEMOTHERAPY No dispute reported 06/30/2026 640729171
Principal investigator 1 PFIZER INC. $7.50 01/22/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671657559
Principal investigator 1 PFIZER INC. $7.50 01/16/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671654889
Principal investigator 1 PFIZER INC. $2,631.25 01/15/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671655331
Principal investigator 1 PFIZER INC. $7.50 01/09/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671657581